Merck Closes Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
Advances Merck’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing
"Novel modalities like cell and gene therapies offer tremendous potential for bringing new curative treatments to patients,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck. “Mirus Bio’s advanced technology, combined with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and help meet the growing demand for these life-saving therapies.”
Mirus Bio specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. These reagents play a critical role in the production of viral vector-based gene therapies. The addition of Mirus Bio’s leading transfection reagents strengthens Merck’s upstream portfolio and allows for an integrated viral vector manufacturing offering.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.